Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat Dose Tapering in Well-Controlled Gout Patients
NCT06622603Phase 4Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of febuxostat in gout (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Proportion of patients with serum urate levels <7.0 mg/dL at 6 months. Started Sep 2025; status: recruiting.
02
Drugs
febuxostat
03
Conditions
gout
Beyond the preview
Go deeper on NCT06622603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622603.